Last reviewed · How we verify
NCT07234591
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
NA trial testing Tyk2 inhibitor in Plaque Psoriasis in 140 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Usynova Pharmaceuticals Ltd. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 140 |
| Start date | 21 October 2025 |
| Primary completion | 30 April 2026 |
| Estimated completion | 30 May 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tyk2 inhibitor — full drug profile →
- Placebo
Conditions studied
- Plaque Psoriasis — all drugs for Plaque Psoriasis →
- Moderate to Severe Plaque Psoriasis — all drugs for Moderate to Severe Plaque Psoriasis →
Sponsor
Usynova Pharmaceuticals Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Plaque Psoriasis or Moderate to Severe Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07234591
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Plaque Psoriasis
Currently open trials in the same condition.
- NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
- NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
- NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
- NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting
- NCT07130604 — Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis · Phase 3 · recruiting
Other Usynova Pharmaceuticals Ltd. trials
Trials by the same sponsor.
- NCT07038720 — A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07234591 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Usynova Pharmaceuticals Ltd.
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07234591.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing